Skip to main content

sl-172154

·Code: SL-172154

sl-172154: developed by 1 company · 1 clinical trial tracked.

sl-172154 evidence translation

What we can confirm

What it means

Source-backed records connect sl-172154 to STTK; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could sl-172154 → STTK affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Shattuck Labs, Inc. (STTK)
Acute Myeloid Leukemia
Phase 1
Clinical Trials (1)

An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

NCT05275439·Phase 1·STTK
Terminated

Primary endpoint: Safety Profile of SL-172154 Monotherapy or in Combination With Azacitidine

Interventionalopen106 targetStarted 2022-03Completion 2025-0223 sites · Canada, United Kingdom, United StatesShattuck Labs, Inc.

Frequently asked questions

Who is developing sl-172154?

sl-172154 is being developed by Shattuck Labs, Inc..

How many clinical trials involve sl-172154?

BioSniper tracks 1 clinical trial involving sl-172154.